By admin 
The strategic leadership transition at the helm of burgeoning biotechnology firms often signals a shift from foundational research toward the rigorous, high-stakes arena of clinical execution. In the latest high-profile move within the life sciences sector, EpilepsyGTx has officially announced the appointment of Dr. Teresa Nunes as its new Chief Medical Officer (CMO). Dr. Nunes joins the company from Allucent, a global clinical research organization (CRO), where she also served as CMO, bringing with her a wealth of experience in navigating the complex regulatory and clinical pathways required to bring transformative therapies to market. This appointment comes at a critical juncture for EpilepsyGTx as it seeks to advance its proprietary gene therapy platform designed to address the unmet needs of patients suffering from focal epilepsy, a condition that remains stubbornly resistant to conventional pharmacological interventions.
The recruitment of Dr. Nunes is a significant coup for EpilepsyGTx, a company that emerged from the world-class neuroscientific research conducted at University College London (UCL). As a spin-out, the company is built upon the pioneering work of Professor Dimitri Kullmann and his colleagues, who have spent decades investigating the molecular mechanisms of neuronal excitability. The transition of a seasoned executive from the service side of the industry—Allucent—to a specialized developer of genetic medicines reflects a broader trend in the biotech ecosystem. Leaders with deep "bench-to-bedside" experience are increasingly sought after by venture-backed startups to bridge the gap between academic brilliance and commercial viability. At Allucent, Dr. Nunes was instrumental in overseeing diverse clinical programs across various therapeutic areas, providing her with a panoramic view of the global regulatory landscape. Her move to EpilepsyGTx suggests a focused commitment to the specialized field of Central Nervous System (CNS) disorders, specifically the burgeoning domain of optogenetics and chemogenetics-inspired gene therapies.
To understand the weight of this appointment, one must look at the current state of epilepsy treatment. Epilepsy affects approximately 50 million people worldwide, making it one of the most common neurological diseases globally. While the market is saturated with anti-epileptic drugs (AEDs), nearly one-third of patients suffer from "refractory" or drug-resistant epilepsy. For these individuals, seizures persist despite trying multiple combinations of medications. Focal epilepsy, where seizures originate in a specific area of the brain, is particularly challenging. Current surgical options involve the resection or ablation of the brain tissue where the seizures originate—a daunting prospect for patients and clinicians alike. EpilepsyGTx is proposing a paradigm shift: instead of cutting out brain tissue, they aim to use gene therapy to "reprogram" the overactive neurons within the seizure focus.
The company’s lead program utilizes an adeno-associated virus (AAV) vector to deliver a therapeutic gene directly into the affected area of the brain. This gene encodes for a protein—often a potassium channel—that serves to dampen neuronal over-excitability. By increasing the threshold required for a neuron to fire, the therapy aims to prevent the runaway electrical activity that characterizes a seizure. Dr. Nunes will be responsible for overseeing the Phase I/II clinical trials that will determine whether this localized approach is both safe and effective in humans. Her experience in clinical trial design will be paramount here, as the delivery of gene therapy to the brain requires sophisticated neurosurgical techniques and precise imaging to ensure the vector reaches the intended target without off-target effects.
Beyond the technical challenges of the science, the business of being a CMO in 2026 involves navigating an increasingly skeptical reimbursement environment. As Pharmalot has frequently explored, the "sticker shock" associated with gene therapies—often ranging from $1 million to $4 million per dose—remains a point of contention among payers, policymakers, and patient advocates. While EpilepsyGTx’s therapy is envisioned as a potentially curative, "one-and-done" treatment, the long-term durability of the gene expression must be proven to justify such costs. Dr. Nunes will likely find herself at the center of these value-based pricing discussions, balancing the need for investor returns with the imperative of patient access.
The broader biotech landscape in which EpilepsyGTx operates is also undergoing a period of intense recalibration. After the "gold rush" years of 2020 and 2021, the industry has faced a more disciplined capital market. Investors are no longer satisfied with promising preclinical data alone; they demand clear clinical proof-of-concept and a viable path to regulatory approval. By bringing in a CMO with a proven track record at a major CRO, EpilepsyGTx is signaling to the market that it is ready for the rigors of late-stage development. Allucent, Dr. Nunes’s previous home, is known for its expertise in helping small and mid-sized biotechs scale their operations. Her departure from the service provider side to the "sponsor" side allows her to apply those scaling strategies directly to a single, high-potential pipeline.
The "Coming/Going" column has long been a staple of the Pharmalot report because these personnel shifts serve as a bellwether for industry health. When talent flows toward a specific therapeutic modality, such as gene therapy for CNS, it indicates a high level of confidence in the underlying technology. However, as the snippet noted, "all work and no play can make for a dull chief medical officer." This sentiment reflects a growing conversation within the C-suite regarding executive burnout and the necessity of maintaining a holistic perspective. The pressure on a CMO at a gene therapy startup is immense; they carry the hopes of patients who have exhausted all other options, alongside the financial expectations of venture capitalists. Dr. Nunes’s move is not just a career advancement but a high-stakes bet on the future of genomic medicine.
Looking ahead, the success of EpilepsyGTx will depend on several factors that Dr. Nunes must now manage. First is the safety profile of the AAV vectors. While AAV has been widely used in approved therapies like Zolgensma and Luxturna, the brain is an immunologically unique environment. Any sign of neuroinflammation or unintended gene expression could stall the program. Second is the competitive landscape. EpilepsyGTx is not alone in its quest. Companies like Taysha Gene Therapies and various academic-led consortia are also exploring genetic approaches to epilepsy. The race to be "first to clinic" and "first to market" is a grueling one. Third is the regulatory environment. The FDA and EMA have become increasingly sophisticated in their evaluation of gene therapies, often requiring long-term follow-up data (up to 15 years in some cases) to monitor for delayed adverse events.
The role of the CMO is also evolving in the context of "patient-centricity." In the past, clinical development was often siloed from the patient experience, focused primarily on biochemical markers and seizure frequency charts. Today, regulators and payers are looking at Quality of Life (QoL) metrics. Does the therapy allow a patient to return to work? Can they drive a car? Does it reduce the cognitive "fog" often associated with high-dose AEDs? Dr. Nunes’s background suggests she is well-positioned to integrate these patient-reported outcomes into the clinical program, ensuring that the data generated is meaningful not just to scientists, but to the people living with epilepsy.
As this new chapter begins for both Dr. Nunes and EpilepsyGTx, the industry will be watching closely. The transition from a CRO to a biotech startup is a path often traveled, but rarely with such high stakes in the neuro-gene therapy space. If successful, the work led by Dr. Nunes could provide a blueprint for treating other focal brain disorders, from Parkinson’s disease to certain forms of chronic pain, using localized genetic modulation. For now, the focus remains on the upcoming clinical milestones. The "Coming/Going" of executives is more than just a game of musical chairs; it is the movement of human capital that drives the next generation of medical breakthroughs. As we track these changes, we see the blueprint of the future of healthcare being drawn, one appointment at a time. The arrival of Teresa Nunes at EpilepsyGTx is a clear indication that the company is moving out of the laboratory and into the clinic, where the true test of their "exciting" new hire and their innovative science will ultimately unfold.
